
Transforming academic
translational research

Expertise in drug
discovery research

Developing for the future
JHDD researchers lead a breakthrough study published in Science Advances showing anti-cancer effects of novel compound DRP-104 that is the basis of a current clinical trial
JHDD-developed glutamine antagonist receives Fast Track designation from FDA for small-cell lung cancer
JHDD-cofounded PSMA Therapeutics acquired by Bayer AG
JHDD coauthors a report showing glutamine antagonism overcomes tumor immune invasion [Science]
JHDD received a UG3 grant through the HEAL initiative to develop new a new treatment for neuropathic pain
Our high throughput screening collaboration with Eisai represents an innovative way to create synergy between complimentary organizations to develop new therapeutics.
We welcome opportunities to discuss how we can work together in a drug discovery collaboration.